KNKeita Nakamori

Keita Nakamori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keita Nakamori has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer

    by Takuya Tsujino, Shogo Yamazaki, Moritoshi Sakamoto, Yuki Yoshikawa, Ryoichi Maenosono, Yuki Nakajima, Kensuke Hirosuna, Tomoaki Takai, Kazuki Nishimura, Mitsuaki Ishida, et al.

    Bladder-preserving trimodality therapy (TMT) incorporating concurrent chemoradiotherapy (CRT) provides a curative-intent alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), yet its efficacy is frequently limited by intrinsic treatment resistance, the molecular basis of which remains poorly defined. To address this, we performed bulk transcriptomic profiling of pretreatment tumors from 179 patients uniformly treated with bladder-preserving CRT and systematically integrated gene expression data with tumor immune features and clinical outcomes. We identified a ferroptosis-suppressive transcriptional signature (FSS) associated with a distinct resistance-associated tumor state that independently stratified radiographic progression-free survival and overall survival following CRT. FSS-high tumors were characterized by inferior outcomes, enrichment of basal/squamous and immune-excluded phenotypes, and reduced intratumoral immune infiltration, whereas FSS-low tumors preferentially exhibited luminal unstable and immune-inflamed features. Consistent with clinical observations, a ferroptosis-suppressive transcriptional program was recapitulated in CRT-resistant bladder cancer cell line models. Genome-wide CRISPR/Cas9 loss-of-function screening further identified core ferroptosis suppressors as functionally relevant dependencies specifically under irradiation stress, and pharmacologic induction of ferroptosis effectively restored radiosensitivity in otherwise resistant cells. Together, these findings support ferroptosis suppression as a biologically relevant resistance-associated state that mechanistically links tumor-intrinsic transcriptional programs to immune contexture and therapeutic vulnerability and provide a translational framework for improved risk stratification and future treatment refinement in bladder-preserving therapy for MIBC.


  • Hypoxia-Induced MicroRNAs Confer Survival Advantage in Bladder Cancer by Fine-Tuning Oncogenic Pathways

    by Takaya Ohno, Yuki Nakajima, Yuki Yoshikawa, Takuya Tsujino, Ryoichi Maenosono, Ko Nakamura, Tomoaki Takai, Taizo Uchimoto, Tatsuo Fukushima, Kazuki Nishimura, et al.

    Introduction: Bladder cancer (BC) is influenced by hypoxic conditions, which promote tumor progression and resistance to therapy. MicroRNAs (miRNAs) play key roles in regulating gene expression under hypoxia. Methods: This study utilized an miRNA array to compare expression profiles under normoxic and hypoxic conditions. We analyzed 1,024 miRNAs, focusing on differentially expressed miRNAs. Survival analysis was performed using a cohort of 408 BC patients from TCGA (The Cancer Genome Atlas). Target prediction for hypoxia-inducible factors (HIFs) and cancer-related genes was performed. Results: Of 1,024 miRNAs, 508 were downregulated and 516 upregulated in hypoxia. Four miRNAs (hsa-miR-210, hsa-miR-4435, hsa-miR-6875, hsa-miR-193b) were upregulated >50-fold, and four (hsa-miR-1250, hsa-miR-1288, hsa-miR-362, hsa-miR-6828) were downregulated. Upregulated miRNAs were associated with a trend toward improved overall survival in 408 BC patients (log-rank p = 0.049). Three downregulated miRNAs targeted HIF-1α, while three upregulated miRNAs targeted HIF-3α. Hsa-miR-210 targeted AGO2 and USP10, with hsa-miR-4435 also targeting AGO2. Conclusion: BC under hypoxia exhibits a specific miRNA profile targeting HIFs and cancer-related genes including AGO2 and USP10, potentially influencing treatment success and survival.

  • Open Access

    Living Kidney Transplantation in a Patient With End‐Stage Kidney Disease Due to Rare Juvenile Nail‐Patella‐Like Renal Disease Without LMX1B Mutation

    by Tomota Okabe, Yuki Nakajima, Kengo Iwatsuki, Ryoichi Maenosono, Takuya Matsuda, Shuya Tsuchida, Takaki Hanamori, Yuya Fujiwara, Keita Nakamori, Tomohisa Matsunaga, et al.

    Nail‐patella syndrome (NPS) is a rare disease characterized by fingernail dysplasia, patellar dysplasia, elbow deformities, and iliac horns, with a prevalence of 1 in 50,000 children. Most cases are caused by LMX1B mutations. Approximately 10%–40% of patients with NPS develop renal dysfunction in early childhood, whereas approximately 30% progress to end‐stage renal disease (ESRD). In addition, a few reports describe NPS without LMX1B mutations, but the mechanism affecting renal function is still unclear. In particular, nail‐patella‐like renal disease (NPLRD) presents solely with nephropathy without the physical changes that are characteristic of NPS. Herein, we report a case of clinicopathological NPLRD with characteristic NPS findings on electron microscopy but without physical features or LMX1B mutation, as confirmed by whole exome sequencing. The patient subsequently progressed to ESRD and underwent living‐related kidney transplantation. Seven years posttransplantation, no renal function‐related events occurred, and the patient returned to social activities without complications.

  • Open Access

    Sex as a biological variable: Mechanistic insights and clinical relevance in solid organ transplantation

    by Yao Xiao, Andreas Schroeter, Friederike Martin, Tomohisa Matsunaga, Keita Nakamori, Maximilian J. Roesel, Marlena Habal, Anita S. Chong, Hao Zhou, Stefan G. Tullius


  • Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma

    by Taizo Uchimoto, Ko Nakamura, Kazumasa Komura, Wataru Fukuokaya, Yusuke Yano, Kazuki Nishimura, Shoko Kinoshita, Kyosuke Nishio, Tatsuo Fukushima, Keita Nakamori, et al.